WO2024045255A1 - Forme cristalline b de tégoprazan et son procédé de préparation - Google Patents

Forme cristalline b de tégoprazan et son procédé de préparation Download PDF

Info

Publication number
WO2024045255A1
WO2024045255A1 PCT/CN2022/122709 CN2022122709W WO2024045255A1 WO 2024045255 A1 WO2024045255 A1 WO 2024045255A1 CN 2022122709 W CN2022122709 W CN 2022122709W WO 2024045255 A1 WO2024045255 A1 WO 2024045255A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal form
crystal
tegoprazan
ether
hours
Prior art date
Application number
PCT/CN2022/122709
Other languages
English (en)
Chinese (zh)
Inventor
曹铭
陈道玉
张姿微
陈玉凤
金飞敏
杨绍波
郑保富
高强
Original Assignee
上海皓元医药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海皓元医药股份有限公司 filed Critical 上海皓元医药股份有限公司
Priority to CN202280030243.2A priority Critical patent/CN117222643A/zh
Publication of WO2024045255A1 publication Critical patent/WO2024045255A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to the crystal form of tegoprazan, more specifically, crystal form B and its preparation method, and belongs to the field of pharmaceutical and chemical technology.
  • Tegoprazan 4-[((4S)-5,7-difluoro-3,4-dihydro-2H-chromen-4-yl)oxy]-N,N,2-tri Methyl-1H-benzimidazole-6-carboxamide, its chemical structural formula is as follows:
  • Tegrazan has been approved for marketing in China and South Korea. Tegrazan is a competitive potassium ion acid blocker (P-CAB) with a unique mechanism of action, rapid onset of action, and rapid onset of relief in 30 minutes. Symptoms; inhibits resting and activated proton pumps at the same time, has a long half-life, and has strong and long-lasting acid suppression effect; no acid activation is required. Clinical trials have proven that the 8-week mucosal healing rate is as high as 98.9%, and it has new iterative advantages such as effectively controlling acid breakthrough at night. This breakthrough innovation will have an important impact on improving patients' quality of life and provide new medication options.
  • P-CAB competitive potassium ion acid blocker
  • Patent JP4481344B2 discloses Tegrazan and its preparation method. The residue is purified by gradient elution column chromatography using a mixed solution of ethyl acetate and methanol to obtain a white solid, which is amorphous.
  • Patent CN107207478B discloses a crystalline form A of Tegrazan, whose X-ray powder diffraction pattern has 2 ⁇ values of 8.1 ⁇ 0.2°, 10.0 ⁇ 0.2°, 12.6 ⁇ 0.2°, 14.9 ⁇ 0.2°, 15.6 ⁇ 0.2°, There are characteristic peaks at 16.5 ⁇ 0.2°, 17.2 ⁇ 0.2°, 19.6 ⁇ 0.2°, 23.1 ⁇ 0.2°, 24.2 ⁇ 0.2°, 28.1 ⁇ 0.2°, 30.2 ⁇ 0.2° and 31.6 ⁇ 0.2°.
  • the invention provides a novel crystal form of tegoprazan and a preparation method thereof.
  • the crystal form has stable physical and chemical properties and can meet the requirements of medicinal stability and hygroscopicity.
  • the preparation method of the crystal form is easy to operate and can be industrialized. Production.
  • the present invention provides a crystal form B (crystal form B or Form B) of tegoprazan with good stability and a preparation method with good reproducibility.
  • the present invention provides a crystal form B of tegoprazan, the X-ray powder diffraction pattern of which has characteristic peaks at 2 ⁇ values of 9.5 ⁇ 0.2° and 14.1 ⁇ 0.2°.
  • the present invention provides a crystalline form B of Tegrazan, whose X-ray powder diffraction pattern has characteristic peaks at 2 ⁇ values of 9.5 ⁇ 0.2° and 14.1 ⁇ 0.2° and has one or more of the following characteristic peaks: 15.4 ⁇ 0.2 °, 16.2 ⁇ 0.2°, 19.1 ⁇ 0.2°, 20.6 ⁇ 0.2°, 21.8 ⁇ 0.2°, 22.8 ⁇ 0.2°, 25.1 ⁇ 0.2°, 28.4 ⁇ 0.2° and 32.2 ⁇ 0.2°.
  • the present invention provides a crystal form B of Tegrazan, whose X-ray powder diffraction pattern has 2 ⁇ values of 9.5 ⁇ 0.2°, 14.1 ⁇ 0.2°, 15.4 ⁇ 0.2°, 16.2 ⁇ 0.2°, 19.1 ⁇ 0.2°, and 20.6 There are characteristic peaks at ⁇ 0.2°, 21.8 ⁇ 0.2°, 22.8 ⁇ 0.2°, 25.1 ⁇ 0.2°, 28.4 ⁇ 0.2° and 32.2 ⁇ 0.2° and one or more of the following characteristic peaks: 9.2 ⁇ 0.2°, 12.9 ⁇ 0.2 °, 13.7 ⁇ 0.2°, 15.9 ⁇ 0.2°, 19.9 ⁇ 0.2°, 21.0 ⁇ 0.2°, 21.6 ⁇ 0.2°, 23.3 ⁇ 0.2°, 24.9 ⁇ 0.2°, 26.0 ⁇ 0.2°, 27.3 ⁇ 0.2° and 30.1 ⁇ 0.2 °.
  • the XRPD pattern of Tegoprazan crystal B is consistent with Figure 1 or Figure 2.
  • the DSC spectrum of crystalline Form B of tegoprazan of the present invention includes an absorption peak at 158.5°C ( ⁇ 0.5°C).
  • the TGA spectrum of Tegoprazan crystal B includes a weight loss of no more than 2% between 0 and 150°C, preferably no more than 0.7%.
  • the present invention also provides a method for preparing Tegoprazan crystal form B, which is characterized in that the method includes:
  • liquid alkane in method (1) is n-heptane;
  • the lipid solvent is ethyl acetate or isopropyl acetate, preferably isopropyl acetate;
  • the mass volume ratio (g:mL) of the mixed solvent of tegoprazan and liquid alkane or liquid alkane and ester solvent is 1:5 to 1:30, preferably It is 1:5 ⁇ 1:20, more preferably 1:5 ⁇ 1:10;
  • the temperature in method (1) is 60-100°C; further preferably, it is 80-100°C;
  • the ether solvent in method (2) is methyl tert-butyl ether;
  • the lipid solvent is ethyl acetate or isopropyl acetate, and further preferably ethyl acetate;
  • the temperature in method (2) is room temperature.
  • the mass volume ratio (g:mL) of the mixed solvent between tegoprazan and ether solvents or ether solvents and ester solvents is 1:5 to 1:40;
  • the solvent in the method (2) is a mixed solvent system of ether and ester solvents, wherein the volume ratio of the ether and ester solvents is 8:1 to 20:1;
  • stirring time in method (1) and method (2) is respectively 24 hours to 96 hours, preferably 48 hours to 72 hours.
  • drying in the method (1) and method (2) is performed at 30-60°C, vacuum or normal pressure blast drying; the drying time is 1-3 hours; preferably, the The drying time stated is 2 hours.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising crystalline form B of tegoprazan and a pharmaceutically acceptable carrier; or, a drug with a competitive potassium ion acid blocker (P-CAB) effect Compositions containing crystalline form B of tegoprazan as an active ingredient; or, preventive or therapeutic drugs for gastroesophageal reflux disease (such as erosive esophagitis, non-erosive reflux disease), duodenal ulcer , which contains crystalline form B of tegoprazan as the active ingredient.
  • gastroesophageal reflux disease such as erosive esophagitis, non-erosive reflux disease
  • duodenal ulcer which contains crystalline form B of tegoprazan as the active ingredient.
  • the compound of Tegrazan formula (1) is a drug with poor water solubility and belongs to BCS II.
  • the crystalline form B provided by the present invention has the highest solubility in gastric acid simulated liquid and is a pH-dependent drug with good solubility; the lower the pH value, the greater the solubility, indicating the higher its oral bioavailability. Solubility reaches 45.7 mg/ml in pH 1.2 hydrochloride buffer solution after 2 hours. It is beneficial to improve the absorption of drugs in the human body and improve bioavailability; in addition, higher solubility can reduce the dosage of drugs while ensuring the efficacy of drugs, thereby reducing the side effects of drugs and improving the safety of drugs.
  • Tegrazan crystal form B provided by the present invention has good stability and low hygroscopicity.
  • TGA thermogravimetric analyzer
  • Tegrazan crystal form B provided by the present invention is physically stable at room temperature. When crystal form B is exposed to an environment of 25°C and 92.5% RH, crystal form B will not absorb water molecules or convert into any other crystal form.
  • Tegolazan crystal form B provided by the invention is stable at room temperature.
  • the chemical purity of the crystal form B is There is no obvious change, and the XRPD spectrum of crystal form B shows no crystallization phenomenon.
  • the DVS isotherm of the crystal form B of tegoprazan provided by the present invention.
  • the crystal form B is slightly hygroscopic ( Figure 5 shows that the moisture absorption amount from 60% RH to 80% RH is only 0.31%), and the XRPD of the sample after the hygroscopicity test
  • the spectra are consistent, that is, there is no risk of crystallization during the adsorption and desorption process.
  • the crystal form B of the present invention is more conducive to industrial production; after comparison, the XRPD spectra of the crystal form B of the present invention and the crystal form A reported in CN107207478B are significantly different, and can be identified as different crystal forms.
  • the new anhydrous crystal form of tegoprazan crystal form B provided by the present invention has a simple preparation method, good reproducibility, and is easier to be industrially produced. And it has good stability (high humidity, light), low hygroscopicity, and meets medicinal requirements. It also has good solubility and is expected to be an ideal drug choice.
  • Figure 1 is an X-ray powder diffraction (XPRD) pattern of crystal form B obtained in Example 1.1 of the present invention
  • Figure 2 is an X-ray powder diffraction (XPRD) pattern of crystal form B obtained in Example 1.2 of the present invention
  • FIG. 3 is a thermogravimetric analysis (TGA) spectrum of crystal form B obtained in Example 1.1 of the present invention
  • Figure 4 is a differential scanning calorimetry (DSC) spectrum of crystal form B obtained in Example 1.1 of the present invention.
  • Figure 5 is a dynamic moisture adsorption (DVS) spectrum of the hygroscopicity test of crystal form B obtained in Example 1.1 of the present invention
  • Figure 6 is an X-ray powder diffraction comparison chart before and after the hygroscopicity test of crystal form B obtained in Example 1.1 of the present invention.
  • Figure 7 is an X-ray powder diffraction comparison chart of crystal form B obtained in Example 1.1 of the present invention before and after stable placement;
  • Figure 8 is a comparative X-ray powder diffraction chart of the crystal form B obtained in Example 1.1 of the present invention before and after being placed for light stability.
  • the XPRD spectrum was collected on a Bruker D8 ADVANCE diffractometer.
  • the parameters of the X-ray powder diffraction method are as follows: X-ray reflection parameters: Cu, K ⁇ ; tube voltage: 40 kilovolts (kV); tube current: 40 Milliamperes (mA); Slits: 2# scattering slit: 1°, 3# anti-scattering slit: 1°, 4# receiving slit: 0.3mm; scanning mode: step; step angle: 0.02°, Sampling time: 0.2s; scanning range: from 3.0 to 40.0 degrees.
  • Embodiment 1 A kind of crystal form B of tegoprazan and its preparation method
  • the crude tegolazan product can be in any solid form of tegolazan, such as the white solid obtained from Example 2 of JP4481344B2.
  • the X-ray powder diffraction pattern of the crystal form B is shown in Figure 1.
  • the X-ray powder diffraction pattern of the crystal form B has 2 ⁇ values of 9.5 ⁇ 0.2°, 14.1 ⁇ 0.2°, 15.4 ⁇ 0.2°, 16.2 ⁇ 0.2°, 19.1 ⁇ 0.2°, 20.6 ⁇ 0.2°, 21.8 ⁇ 0.2°, 22.8 ⁇ 0.2°, 25.1 ⁇ 0.2°, 28.4 ⁇ 0.2° and 32.2 ⁇ 0.2° and one or more of the following positions: 9.2 ⁇ 0.2 °, 12.9 ⁇ 0.2°, 13.7 ⁇ 0.2°, 15.9 ⁇ 0.2°, 19.9 ⁇ 0.2°, 21.0 ⁇ 0.2°, 21.6 ⁇ 0.2°, 23.3 ⁇ 0.2°, 24.9 ⁇ 0.2°, 26.0 ⁇ 0.2°, 27.3 ⁇ 0.2 There are characteristic peaks at 30.1 ⁇ 0.2°.
  • the TGA spectrum of the crystal form B is shown in Figure 3, and the DSC spectrum is shown in Figure 4.
  • the results show that the TGA data of the Tegolazan crystal form B shows that the crystal form is heated between 0 and 150°C. There is a weight loss of about 0.67%, and there is a single melting endothermic peak between 164°C and 200°C in DSC, indicating that the crystal form is anhydrous tegoprazan.
  • the X-ray powder diffraction pattern measured using Cu-K ⁇ rays on the prepared crystals is the same as that in Example 1.1.
  • the X-ray powder diffraction pattern measured using Cu-K ⁇ rays on the prepared crystals is the same as that in Example 1.1.
  • Table 1 show that the crystal form B of the present invention can be stored at least 10 times when stored under three different humidity and temperature conditions in Table 1 (25°C/60%RH, 40°C/75%RH or 25°C/92.5%RH). Two weeks later, as shown in Figure 7, there was no change in the X-ray powder diffraction before and after the stability of the crystal form B obtained by the present invention was placed. Crystalline Form B and Form A of tegoprazan of the present invention have equivalent stability. The physical form and chemical purity still have good stability under high temperature and high humidity conditions.
  • the crystal form A prepared in the comparative example and the crystal form B prepared in Example 1.1 were placed in a light stability box until the total illumination was 1.2 ⁇ 10 6 Lux ⁇ hr. They were taken out for testing by XRPD and HPLC. The experimental results are shown in Table 2. :

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une forme cristalline B du tégoprazan. Un motif de diffraction de rayons X sur poudre de celle-ci a des pics caractéristiques à des valeurs 2θ de 9,5 ± 0,2° et 14,1 ± 0,2° et a un ou plusieurs des pics caractéristiques suivants : 15,4 ± 0,2°, 16,2 ± 0,2°, 19,1 ± 0,2°, 20,6 ± 0,2°, 21,8 ± 0,2°, 22,8 ± 0,2°, 25,1 ± 0,2°, 28,4 ± 0,2° et 32,2 ± 0,2°. La forme cristalline B a un procédé de préparation simple, a une bonne reproductibilité, et a de faibles exigences pour le procédé de préparation et les conditions de stockage. De plus, la forme cristalline B présente une bonne stabilité et une faible hygroscopicité. La forme cristalline B n'a pas de changement évident de sa pureté chimique, lorsqu'elle est exposée à une humidité élevée RH à 25 °C/92,5 % et à un environnement éclairé, et la forme cristalline n'a également pas de changement dans son motif de diffraction de rayons X sur poudre. La forme cristalline B a une forte valeur médicinale.
PCT/CN2022/122709 2022-08-30 2022-09-29 Forme cristalline b de tégoprazan et son procédé de préparation WO2024045255A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202280030243.2A CN117222643A (zh) 2022-08-30 2022-09-29 一种特戈拉赞晶型b及其制备方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211060454 2022-08-30
CN202211060454.9 2022-08-30

Publications (1)

Publication Number Publication Date
WO2024045255A1 true WO2024045255A1 (fr) 2024-03-07

Family

ID=90100258

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/122709 WO2024045255A1 (fr) 2022-08-30 2022-09-29 Forme cristalline b de tégoprazan et son procédé de préparation

Country Status (1)

Country Link
WO (1) WO2024045255A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101341149A (zh) * 2005-12-19 2009-01-07 辉瑞大药厂 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途
CN107207478A (zh) * 2015-01-20 2017-09-26 Cj医药健康株式会社 苯并咪唑衍生物的新型结晶形式及其制备方法
CN111303131A (zh) * 2020-03-19 2020-06-19 海门慧聚药业有限公司 特戈拉赞(Tegoprazan)类似物及其合成方法
CN112851646A (zh) * 2019-11-12 2021-05-28 中国医学科学院药物研究所 特戈拉赞的制备方法
CN113527272A (zh) * 2021-08-06 2021-10-22 西安淳甄新材料有限公司 一种特戈拉赞的合成方法
CN114805317A (zh) * 2022-05-20 2022-07-29 江苏威奇达药业有限公司 一种特戈拉赞的制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101341149A (zh) * 2005-12-19 2009-01-07 辉瑞大药厂 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途
CN107207478A (zh) * 2015-01-20 2017-09-26 Cj医药健康株式会社 苯并咪唑衍生物的新型结晶形式及其制备方法
CN112851646A (zh) * 2019-11-12 2021-05-28 中国医学科学院药物研究所 特戈拉赞的制备方法
CN111303131A (zh) * 2020-03-19 2020-06-19 海门慧聚药业有限公司 特戈拉赞(Tegoprazan)类似物及其合成方法
CN113527272A (zh) * 2021-08-06 2021-10-22 西安淳甄新材料有限公司 一种特戈拉赞的合成方法
CN114805317A (zh) * 2022-05-20 2022-07-29 江苏威奇达药业有限公司 一种特戈拉赞的制备方法

Similar Documents

Publication Publication Date Title
JP7086118B2 (ja) Ｌ－オルニチンフェニルアセテートおよびその製造方法
WO2021093809A1 (fr) Forme cristalline de tafamidis ainsi que son procédé de préparation et son utilisation
JP2006515338A (ja) クロピドグレルのベンゼンスルホン酸塩および医薬製剤を製造するためのその使用
WO2021136477A1 (fr) Co-cristal de dichlorhydrate du composé i et son procédé de préparation et son utilisation
WO2022007629A1 (fr) Forme cristalline d'upadacitinib, son procédé de préparation et son utilisation
CA3035124A1 (fr) Forme polymorphe d'un compose inhibiteur de kinase, composition pharmaceutique le contenant, son procede de preparation et son utilisation
WO2014082354A1 (fr) Forme cristalline de chidamide, procédé de préparation et utilisation correspondants
JP2016183193A (ja) フィダキソマイシンの固体状形態およびその調製方法
US20220372021A1 (en) Resmetirom crystal, preparation method for same, and uses thereof
CA2829687A1 (fr) Nouvelle forme cristalline vii d'agomelatine, son procede de preparation et utilisation et composition pharmaceutique la contenant
CA2829690C (fr) Agomelatine cristalline mixte (forme viii), son procede de preparation et utilisation et composition pharmaceutique la contenant
WO2024045255A1 (fr) Forme cristalline b de tégoprazan et son procédé de préparation
CN109897009B (zh) 一种Apabetalone水合物晶型及其制备方法
WO2019205812A1 (fr) Nouvelle forme cristalline de l'acalabrutinib, son procédé de préparation et son utilisation
WO2017206827A1 (fr) Forme cristalline de l'inhibiteur du cotransporteur de sodium-glucose de type 2
WO2018024236A1 (fr) Nouvelle forme cristalline d'inhibiteur sélectif de jak1, son procédé de fabrication et son application
US10233144B2 (en) Crystalline form of AHU377, preparation method and use thereof
US10577341B1 (en) Beraprost-314d monohydrate crystals and methods for preparation thereof
JPWO2005103017A1 (ja) 難溶性薬物の比表面積増大方法
CN117222643A (zh) 一种特戈拉赞晶型b及其制备方法
WO2024153063A1 (fr) Forme cristalline d'enpatoran, son procédé de préparation et son utilisation
WO2024027013A1 (fr) Forme cristalline ii d'elobixibat et son procédé de préparation
WO2024179558A1 (fr) Forme cristalline de pirtobrutinib, son procédé de préparation et son utilisation
WO2020151672A1 (fr) Forme cristalline de dapagliflozine, son procédé de préparation et son utilisation
WO2024067844A9 (fr) Forme cristalline d'hydrochlorure de fexuprazan, son procédé de préparation et son utilisation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 202280030243.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22957074

Country of ref document: EP

Kind code of ref document: A1